Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference
September 09 2021 - 7:30AM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers, today announced a poster presentation of new
preclinical data on OP-1250, a complete estrogen receptor (ER)
antagonist (CERAN) and a selective ER degrader (SERD) being
developed for the treatment of metastatic breast cancer and other
women’s cancers, at the 1st JCA-AACR Precision Cancer Medicine
International Conference being held virtually from September 10-12,
2021 (U.S.) and September 11-12 (Japan).
A virtual e-poster presentation titled, "Complete
Estrogen Receptor (ER) Antagonism As An Optimal Approach for
ER-Positive Breast Cancer Drug Development," along with a
pre-recorded audio narration will be available on-demand on the
conference website.
About Olema OncologyOlema Oncology
is a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers. Olema’s lead product candidate, OP-1250, is an
orally-available small molecule with combined activity as both a
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD). It is currently being evaluated as a single
agent in an ongoing Phase 1/2 clinical trial in patients with
recurrent, locally advanced or metastatic ER-positive (ER+), human
epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Olema is headquartered in San Francisco.
Forward Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Words such as “anticipate,” “expect,”
“intend,” “will,” “may,” “goal,” “estimate,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These statements
include those related to the development of OP-1250, including
timelines related to data presentation, trial initiation and
advancement, and enrollment, as well as the sufficiency of our
financial resources. Because such statements deal with future
events and are based on Olema’s current expectations, they are
subject to various risks and uncertainties, and actual results,
performance or achievements of Olema could differ materially from
those described in or implied by the statements in this press
release. These forward-looking statements are subject to risks and
uncertainties, including, without limitation, the risk that Olema’s
ongoing or future clinical studies in humans may show that OP-1250
is not a tolerable and effective treatment for breast cancer and
other risks and uncertainties affecting Olema, as well as those
discussed in the section titled “Risk Factors” in Olema’s Quarterly
Report on Form 10-Q for the quarter ended June 30, 2021 to be filed
on August 10, 2021 and future filings and reports that Olema makes
from time to time with the United States Securities and Exchange
Commission. Except as required by law, Olema assumes no obligation
to update these forward-looking statements or to update the reasons
if actual results differ materially from those anticipated in the
forward-looking statements.
Contact:Eva StroynowskiVice President,
Communications and Investor Relationseva@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2023 to Jul 2024